Cutaneous head and neck melanoma: the old and the new

References

• Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer83(8), 1664–1678 (1998).
   PubMed Web of Science ®Google Scholar
• Hicks MJ, Flaitz CM. Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol.36(2), 152–169 (2000).
   PubMed Web of Science ®Google Scholar
• Ries LAG, Melbert D, Krapcho M et al. (Eds). SEER Cancer Statistics Review, 1975–2004. National Cancer Institute, Bethesda, MD, USA, (2007).
   Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• MacKie RM. Incidence, risk factors and prevention of melanoma. Eur. J. Cancer34(Suppl. 3), S3–S6 (1998).
   PubMed Web of Science ®Google Scholar
• Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br. J. Dermatol.155(4), 771–777 (2006).
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res.29(3), 705–727 (1969).
   PubMed Web of Science ®Google Scholar
• Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg.172(5), 902–908 (1970).
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol.19(16), 3622–3634 (2001).
   PubMed Web of Science ®Google Scholar
• Balch CM, Wilkerson JA, Murad TM et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer45(12), 3012–3017 (1980).
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J. Clin. Oncol.17(3), 976–983 (1999).
   PubMed Web of Science ®Google Scholar
• Moehrle M, Kraemer A, Schippert W et al. Clinical risk factors and prognostic significance of local recurrence in cutaneous melanoma. Br. J. Dermatol.151(2), 397–406 (2004).
   PubMedGoogle Scholar
• Handley W. The pathology of melanotic growths in relation to their operative treatment. Lancet1, 927–935 (1907).
   Google Scholar
• Cochran AJ. Studies of the melanocytes of the epidermis adjacent to tumors. J. Invest. Dermatol.57(1), 38–43 (1971).
   PubMedGoogle Scholar
• Olsen G. The malignant melanoma of the skin. New theories based on a study of 500 cases. Acta Chir. Scand. Suppl.365, 1–222 (1966).
   Google Scholar
• Elberg JJ, Poulsen H, Ladefoged C. The influence of resection margin on prognosis in clinical stage I malignant melanoma of the lower leg. Scand. J. Plast. Reconstr. Surg. Hand Surg.23(1), 59–63 (1989).
   Google Scholar
• Goldman LI, Byrd R. Narrowing resection margins for patients with low-risk melanoma. Am. J. Surg.155(2), 242–244 (1988).
   Google Scholar
• Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch. Surg.126(4), 438–441 (1991).
   PubMedGoogle Scholar
• Veronesi U, Cascinelli N, Adamus J et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm.N. Engl. J. Med.318(18), 1159–1162 (1988).
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Smith T et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann. Surg. Oncol.8(2), 101108 (2001).
   PubMed Web of Science ®Google Scholar
• Balch CM, Urist MM, Karakousis CP et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann. Surg.218(3), 262–267; discussion 267–269 (1993).
   PubMed Web of Science ®Google Scholar
• Cohn-Cedermark G, Rutqvist LE, Andersson R et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. Cancer89(7), 1495–1501 (2000).
   PubMed Web of Science ®Google Scholar
• Ringborg U, Andersson R, Eldh J et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer77(9), 1809–1814 (1996).
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Santinami M, Maurichi A, Patuzzo R, Pennacchioli E. World Health Organization experience in the treatment of melanoma. Surg. Clin. North Am.83(2), 405–416 (2003).
   PubMed Web of Science ®Google Scholar
• Cascinelli N. Margin of resection in the management of primary melanoma. Semin. Surg. Oncol.14(4), 272–275 (1998).
   Google Scholar
• Piepkorn M. Melanoma resection margin recommendations, unconventionally based on available facts. Semin. Surg. Oncol.15(3), 230–234 (1998).
   Google Scholar
• O’Brien CJ, Gianoutsos MP, Morgan MJ. Neck dissection for cutaneous malignant melanoma. World J. Surg.16(2), 222–226 (1992).
   PubMed Web of Science ®Google Scholar
• van Akkooi AC, Bouwhuis MG, van Geel AN et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur. J. Surg. Oncol.33(1), 102–108 (2007).
   PubMed Web of Science ®Google Scholar
• McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg. Gynecol. Obstet.161(6), 575–580 (1985).
   PubMedGoogle Scholar
• Balch CM, Soong S, Ross MI et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann. Surg. Oncol.7(2), 87–97 (2000).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Adamus J, Bandiera DC et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N. Engl. J. Med.297(12), 627–630 (1977).
   PubMed Web of Science ®Google Scholar
• Fisher SR. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998. Laryngoscope112(1), 99–110 (2002).
   PubMedGoogle Scholar
• de Wilt JH, Thompson JF, Uren RF et al. Correlation between preoperative lymphoscintigraphy and metastatic nodal disease sites in 362 patients with cutaneous melanomas of the head and neck. Ann. Surg.239(4), 544–552 (2004).
   PubMed Web of Science ®Google Scholar
• O’Brien CJ, Uren RF, Thompson JF et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am. J. Surg.170(5), 461–466 (1995).
   PubMed Web of Science ®Google Scholar
• Rigual NR, Cheney RT, Iwenofu OH et al. Idiosyncrasies of scalp melanoma. Laryngoscope117(8), 1354–1358 (2007).
   Google Scholar
• Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg.127(4), 392–399 (1992).
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med.355(13), 1307–1317 (2006).
   PubMed Web of Science ®Google Scholar
• Rasgon BM. Use of low-dose technetium Tc 99m sulfur colloid to locate sentinel lymph nodes in melanoma of the head and neck: preliminary study. Laryngoscope111(8), 1366–1372 (2001).
   Google Scholar
• Urist MM, Balch CM, Soong SJ et al. Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann. Surg.200(6), 769–775 (1984).
   PubMed Web of Science ®Google Scholar
• Pathak I, O’Brien CJ, Petersen-Schaeffer K et al. Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? Head Neck23(9), 785–790 (2001).
   Google Scholar
• Lin D, Franc BL, Kashani-Sabet M, Singer MI. Lymphatic drainage patterns of head and neck cutaneous melanoma observed on lymphoscintigraphy and sentinel lymph node biopsy. Head Neck28(3), 249–255 (2006).
   PubMed Web of Science ®Google Scholar
• Ollila DW, Foshag LJ, Essner R, Stern SL, Morton DL. Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma. Ann. Surg. Oncol.6(2), 150–154 (1999).
   PubMedGoogle Scholar
• Loree TR, Tomljanovich PI, Cheney RT, Hicks WL Jr, Rigual NR. Intraparotid sentinel lymph node biopsy for head and neck melanoma. Laryngoscope116(8), 1461–1464 (2006).
   PubMedGoogle Scholar
• Chao C, Wong SL, Edwards MJ et al. Sentinel lymph node biopsy for head and neck melanomas. Ann. Surg. Oncol.10(1), 21–26 (2003).
   PubMedGoogle Scholar
• Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann. Surg.230(4), 453–463; discussion 463–455 (1999).
   PubMed Web of Science ®Google Scholar
• Sondak VK, Taylor JM, Sabel MS et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann. Surg. Oncol.11(3), 247–258 (2004).
   PubMed Web of Science ®Google Scholar
• Gershenwald JE SS TJ. Prognostic factors and natural history. In: Cutaneous Melanoma. Balch CM, Houghton A Jr, Sober A, Soong SJ (Eds). Quality Medical Publishing, St Louis, MO, USA (2003).
   Google Scholar
• Banzet P, Jacquillat C, Civatte J et al. Adjuvant chemotherapy in the management of primary malignant melanoma. Cancer41(4), 1240–1248 (1978).
   PubMed Web of Science ®Google Scholar
• Karakousis CP, Emrich LJ. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG. J. Surg. Oncol.36(4), 235–238 (1987).
   Google Scholar
• Veronesi U, Adamus J, Aubert C et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N. Engl. J. Med.307(15), 913–916 (1982).
   PubMed Web of Science ®Google Scholar
• Lipton A, Harvey HA, Lawrence B et al. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer51(1), 57–60 (1983).
   PubMed Web of Science ®Google Scholar
• Morton DL, Eilber FR, Holmes EC et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann. Surg.180(4), 635–643 (1974).
   PubMed Web of Science ®Google Scholar
• Loutfi A, Shakr A, Jerry M, Hanley J, Shibata HR. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin. Invest. Med.10(4), 325–328 (1987).
   PubMed Web of Science ®Google Scholar
• Parkinson DR. Levamisole as adjuvant therapy for melanoma: quo vadis? J. Clin. Oncol.9(5), 716–717 (1991).
   Google Scholar
• Spitler LE. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J. Clin. Oncol.9(5), 736–740 (1991).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol.19(9), 2370–2380 (2001).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol.14(1), 7–17 (1996).
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon α-2b. J. Clin. Oncol.22(1), 11–14 (2004).
   PubMedGoogle Scholar
• Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res.11(1), 75–81 (2001).
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol.4(12), 748–759 (2003).
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Stickley M, Watt P et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J. Clin. Oncol.24(19), 3172–3177 (2006).
   PubMed Web of Science ®Google Scholar
• Daryanani D, Plukker JT, de Jong MA et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res.15(2), 119–124 (2005).
   Google Scholar
• Leong SP, Accortt NA, Essner R et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch. Otolaryngol. Head Neck Surg.132(4), 370–373 (2006).
   PubMedGoogle Scholar
• Dewey DL. The radiosensitivity of melanoma cells in culture. Br. J. Radiol.44(526), 816–817 (1971).
   PubMed Web of Science ®Google Scholar
• Sause WT, Cooper JS, Rush S et al. Fracture size in external beam radiation therapy in the treatment of melanoma. Int. J. Radiol. Biol. Phys.20, 429–432 (1991).
   PubMed Web of Science ®Google Scholar
• Diener-West M, Earle JD, Fine SL et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18 Arch. Ophthalmol.119(7), 969–982 (2001).
   PubMedGoogle Scholar
• Harwood AR, Lawson VG. Radiation therapy for melanomas of the head and neck. Head Neck Surg.4(6), 468–474 (1982).
   PubMedGoogle Scholar
• Ang KK, Peters LJ, Weber RS et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int. J. Radiat. Oncol. Biol. Phys.30(4), 795–798 (1994).
   PubMed Web of Science ®Google Scholar
• Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother. Oncol.5(3), 183–192 (1986).
   PubMed Web of Science ®Google Scholar
• Lee RJ, Gibbs JF, Proulx GM et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.46(2), 467–474 (2000).
   PubMed Web of Science ®Google Scholar
• Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park, NY)18(1), 99–107; discussion 107–110, 113–104 (2004).
   PubMedGoogle Scholar
• Markovic SN, Erickson LA, Rao RD et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin. Proc.82(4), 490–513 (2007).
   PubMed Web of Science ®Google Scholar
• Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope109(2 Pt 1), 208–211 (1999).
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Amdur RJ, Hinerman RW et al. Head and neck mucosal melanoma. Am J. Clin. Oncol.28(6), 626–630 (2005).
   Google Scholar
• Krengli M, Masini L, Kaanders JH et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int. J. Radiat. Oncol. Biol. Phys.65(3), 751–759 (2006).
   PubMed Web of Science ®Google Scholar
• Krengli M, Jereczek-Fossa BA, Kaanders JH et al. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit. Rev. Oncol. Hematol.65(2), 121–128 (2008).
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med.354(7), 709–718 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Wrzesinski C et al. Increased intensity lymphodepletion and adoptive immunotherapy – how far can we go? Nat. Clin. Pract. Oncol.3(12), 668–681 (2006).
   PubMedGoogle Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer VC, Karasarides M, Hayward R, Marais R. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res.67(1), 122–129 (2007).
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS et al. High frequency of BRAF mutations in nevi. Nat. Genet.33(1), 19–20 (2003).
   PubMed Web of Science ®Google Scholar
• Agarwala S, Keilholz U, Hogg D et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J. Clin. Oncol.25(1), 8510 (2007).
   Web of Science ®Google Scholar
• Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Dev. Genes Evol.20(16), 2149–2182 (2006).
   Google Scholar